SCHEMBL25368567

SCHEMBL25368567

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)NCc3ccc(N4CCOCC4)cc3)cs2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.54
▸ NR1H4 Q96RI1 4/20 0.54
▸ NAMPT P43490 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PTK2 Q05397 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ PSMD14 O00487 1/20 0.42
▸ STAMBP O95630 1/20 0.42
▸ COPS5 Q92905 1/20 0.42
▸ DHX9 Q08211 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543894 1.00 EPHX2 (0.54) EPHX2NR1H4NAMPTKDM4EPOLB
SCHEMBL25370300 0.91 ALDH1A1 (0.51) EPHX2NR1H4KDM4EPOLBLMNA
SCHEMBL30543961 0.91 ALDH1A1 (0.51) EPHX2NR1H4KDM4EPOLBLMNA
SCHEMBL30543936 0.83 NPC1 (0.56) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL25370105 0.83 NPC1 (0.56) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL25433357 0.77 NFATC1 (0.54) EPHX2MEN1KMT2ABCHEDHX9
SCHEMBL30543915 0.77 ALDH1A1 (0.46) EPHX2NAMPTLMNAALDH1A1BCHE
SCHEMBL25367979 0.77 ALDH1A1 (0.46) EPHX2NAMPTLMNAALDH1A1BCHE
SCHEMBL25367270 0.76 MAPK14 (0.47) KDM4EPOLBALDH1A1HTTSMN1; SMN2
SCHEMBL25368505 0.76 DHX9 (0.47) EPHX2KDM4EPOLBMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B EPHX2 628/4885NR1H4 2542/4885NAMPT 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback